MCID: MST002
MIFTS: 47

Mast-Cell Leukemia

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Mast-Cell Leukemia

MalaCards integrated aliases for Mast-Cell Leukemia:

Name: Mast-Cell Leukemia 12 14
Leukemia, Mast-Cell 42 69
Mast Cell Leukemia 29
Leukemia Mast Cell 52

Classifications:



External Ids:

Disease Ontology 12 DOID:9254
ICD10 33 C94.3 C94.30
MeSH 42 D007946
NCIt 47 C3169
UMLS 69 C0023461

Summaries for Mast-Cell Leukemia

Disease Ontology : 12 A leukemia that results_in an overwhelming number of tissue mast cells located in peripheral blood.

MalaCards based summary : Mast-Cell Leukemia, also known as leukemia, mast-cell, is related to aleukemic mast cell leukemia and classic mast cell leukemia. An important gene associated with Mast-Cell Leukemia is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Ketamine and Darbepoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and hematopoietic system

Wikipedia : 72 Mast cell leukemia is an extremely aggressive subtype of acute myeloid leukemia that usually occurs de... more...

Related Diseases for Mast-Cell Leukemia

Diseases related to Mast-Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Related Disease Score Top Affiliating Genes
1 aleukemic mast cell leukemia 12.2
2 classic mast cell leukemia 12.1
3 systemic mastocytosis 11.4
4 mast-cell sarcoma 11.0
5 leukemia 10.6
6 venous hemangioma 10.6 KIT KITLG
7 cutaneous solitary mastocytoma 10.6 KIT KITLG
8 adult brainstem gliosarcoma 10.6 KIT KITLG
9 cough variant asthma 10.6 KIT KITLG
10 rhabdoid cancer 10.5 KIT KITLG
11 exertional headache 10.5 KIT KITLG
12 epidermolysis bullosa simplex-mcr 10.5 KIT KITLG
13 punctate palmoplantar keratoderma type 2 10.4 KDR KIT
14 alcohol-induced mental disorder 10.4 KDR KIT
15 periventricular nodular heterotopia 3 10.4 KIT KITLG
16 myoepithelial carcinoma 10.4 KDR KIT
17 stargardt macular degeneration absent or hypoplastic corpus callosum mental retardation and dysmorphic features 10.4 CCL2 CCL5
18 kidney hypertrophy 10.4 KIT KITLG
19 factitious disorder 10.4 KDR KIT
20 temporal lobe epilepsy 10.3 KIT KITLG
21 cask-related intellectual disability 10.3 KDR KIT
22 myofascial pain syndrome 10.3 CCL2 CCL5
23 extraosseous osteosarcoma 10.3 KDR KIT
24 hypereosinophilic syndrome, idiopathic, resistant to imatinib 10.3 KIT KITLG
25 ovarian mucinous adenofibroma 10.3 CCL2 CCL5
26 pneumoconiosis 10.3 CCL2 CCL5
27 mitral valve stenosis 10.3 KDR KIT
28 benign mammary dysplasia 10.2 KIT KITLG
29 proliferative glomerulonephritis 10.1 KIT NTRK3
30 dermatitis herpetiformis, familial 10.1 CCL2 CCL5
31 polyosteolysis/hyperostosis syndrome 10.0 KIT NTRK3
32 myeloid leukemia 10.0
33 carcinoma arising in nasal papillomatosis 10.0 CCL2 CCL5
34 lung clear cell-sugar-tumor 10.0 KIT NTRK3
35 status epilepticus 9.9 CCL2 CCL5
36 gestational choriocarcinoma 9.9 KIT NTRK3
37 mast cell disease 9.9
38 cutaneous mastocytosis 9.9
39 aggressive systemic mastocytosis 9.9
40 histiocytic and dendritic cell cancer 9.8 CCL2 CCL5 KDR
41 olfactory nerve disease 9.7 KIT KITLG NTRK3
42 gastrointestinal stromal tumor 9.7 KIT KITLG NTRK3
43 asthma 9.7
44 reticulum cell sarcoma 9.7
45 hematopoietic stem cell transplantation 9.7
46 portal hypertension 9.7
47 sarcoma 9.7
48 urticaria pigmentosa 9.7
49 urticaria 9.7
50 histiocytosis 9.7

Graphical network of the top 20 diseases related to Mast-Cell Leukemia:



Diseases related to Mast-Cell Leukemia

Symptoms & Phenotypes for Mast-Cell Leukemia

GenomeRNAi Phenotypes related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.07 KDR BTK CCL2 KIT
2 Decreased viability GR00221-A-2 10.07 KDR NTRK3 BTK
3 Decreased viability GR00221-A-3 10.07 KDR BTK
4 Decreased viability GR00221-A-4 10.07 CCL2 KDR NTRK3 BTK
5 Decreased viability GR00301-A 10.07 BTK KIT
6 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 SYT1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.84 KIT BTK
8 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.84 SYT1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.84 BTK
10 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.84 KDR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.84 SYT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.84 NTRK3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.84 NTRK3 BTK
14 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.84 BTK
15 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.84 NTRK3 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.84 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.84 SYT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.84 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.84 SYT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 BTK
21 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 KIT NTRK3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 KDR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.84 BTK
24 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.84 NTRK3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.84 KIT NTRK3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 BTK
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 NTRK3 SYT1 BTK KDR KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.84 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.84 KIT
30 Decreased substrate adherent cell growth GR00193-A-1 9.63 BTK KIT
31 Decreased substrate adherent cell growth GR00193-A-2 9.63 KIT
32 Decreased substrate adherent cell growth GR00193-A-4 9.63 BTK KDR KIT

MGI Mouse Phenotypes related to Mast-Cell Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 BTK CCL5 KDR KIT KITLG RASGRP4
2 immune system MP:0005387 9.17 BTK CCL2 CCL5 KDR KIT KITLG

Drugs & Therapeutics for Mast-Cell Leukemia

Drugs for Mast-Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
3
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
4
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
5 Analgesics Phase 3,Phase 2
6 Anesthetics Phase 3
7 Anesthetics, Dissociative Phase 3
8 Anesthetics, General Phase 3
9 Anesthetics, Intravenous Phase 3
10 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
11 Excitatory Amino Acid Antagonists Phase 3
12 Excitatory Amino Acids Phase 3
13 Neurotransmitter Agents Phase 3
14 Peripheral Nervous System Agents Phase 3,Phase 2
15 Ferric Compounds Phase 3
16 ferric gluconate Phase 3
17 Hematinics Phase 3,Phase 2
18 Analgesics, Opioid Phase 3
19 Narcotics Phase 3
20 Iron Supplement Nutraceutical Phase 3
21
Sunitinib Approved, Investigational Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
22
alemtuzumab Approved, Investigational Phase 2 216503-57-0
23
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
24
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
25
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
26
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
27
Vidarabine Approved Phase 2,Phase 1 24356-66-9 32326 21704
28
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
29
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
30
Busulfan Approved, Investigational Phase 2 55-98-1 2478
31
Levoleucovorin Approved Phase 2 68538-85-2
32
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
33
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
34
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36
rituximab Approved Phase 2 174722-31-7 10201696
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1,Early Phase 1 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
39 Staurosporine Experimental Phase 2 62996-74-1
40
Doxil Approved June 1999 Phase 1, Phase 2 31703
41 4'-N-benzoylstaurosporine Phase 2
42 Protein Kinase Inhibitors Phase 2
43 Specific substance maruyama Phase 2
44 Angiogenesis Inhibitors Phase 2,Phase 1
45 Angiogenesis Modulating Agents Phase 2,Phase 1
46 Anti-Bacterial Agents Phase 2,Phase 1
47 Antibiotics, Antitubercular Phase 2,Phase 1
48 Antibodies Phase 2
49 Antibodies, Monoclonal Phase 2
50 Antifungal Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 55)

id Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
3 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
4 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Midostaurin in Indolent Systemic Mastocytosis Unknown status NCT01920204 Phase 2 Midostaurin,
7 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
8 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
9 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
10 Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Completed NCT00493129 Phase 2 Ontak (Denileukin Diftitox)
11 Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer Completed NCT00627666 Phase 2 busulfan;fludarabine phosphate;leucovorin calcium;methotrexate
12 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
13 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
14 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
15 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
16 Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Completed NCT00186628 Phase 2 Cixutumumab;Paclitaxel
17 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Recruiting NCT01807598 Phase 2 brentuximab vedotin
18 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Recruiting NCT02415608 Phase 2 Ibrutinib
19 Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Active, not recruiting NCT00782067 Phase 2 Midostaurin (PKC412)
20 Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Active, not recruiting NCT00233454 Phase 2 Midostaurin
21 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
22 CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKes) for CD33+ Hem Malignancies Not yet recruiting NCT03214666 Phase 1, Phase 2 161533 with Bolus Test Dose;161533 Only
23 Sunitinib in Treating Patients With Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
24 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
25 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
26 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
27 Quality of Life in Younger Leukemia and Lymphoma Survivors Completed NCT00956475 Phase 1
28 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies Recruiting NCT02561988 Phase 1 BLU-285
29 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting NCT02571036 Phase 1 DCC-2618
30 Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Unknown status NCT00897767
31 Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy Unknown status NCT00670917
32 Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer Unknown status NCT01295463
33 Patient-Reported Outcome Questionnaire for Systemic Mastocytosis Completed NCT02380222
34 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed NCT00112593 fludarabine phosphate;cyclosporine;mycophenolate mofetil
35 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Completed NCT01199562 ganciclovir;valganciclovir;foscarnet sodium
36 S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers Completed NCT00996047
37 Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial Completed NCT00890435
38 Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone Completed NCT00993694 chemotherapy;dapsone
39 Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases Completed NCT00376922
40 Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia Recruiting NCT01869777
41 Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Recruiting NCT00898079
42 Mast Cell Connect: A Registry for Patients With Mastocytosis Recruiting NCT02620254
43 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer Recruiting NCT01137643
44 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Recruiting NCT00935090
45 Registry of Older Patients With Cancer Recruiting NCT01137825
46 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer Active, not recruiting NCT01053494
47 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235 fludarabine phosphate;cyclosporine;mycophenolate mofetil
48 Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases Active, not recruiting NCT00424242 Early Phase 1 Pemetrexed
49 Studying Fentanyl in Patients With Cancer Terminated NCT00899951 fentanyl citrate
50 Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer Terminated NCT00726830 methadone hydrochloride;morphine sulfate;oxycodone hydrochloride

Search NIH Clinical Center for Mast-Cell Leukemia

Cochrane evidence based reviews: leukemia, mast-cell

Genetic Tests for Mast-Cell Leukemia

Genetic tests related to Mast-Cell Leukemia:

id Genetic test Affiliating Genes
1 Mast Cell Leukemia 29

Anatomical Context for Mast-Cell Leukemia

MalaCards organs/tissues related to Mast-Cell Leukemia:

39
Myeloid, Bone, Bone Marrow, Breast, Monocytes

Publications for Mast-Cell Leukemia

Articles related to Mast-Cell Leukemia:

(show top 50) (show all 67)
id Title Authors Year
1
Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. ( 28599188 )
2017
2
Acute Mast Cell Leukemia Associated with t(4;5)(q21;q33). ( 28412213 )
2017
3
Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation. ( 28840997 )
2017
4
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. ( 28255023 )
2017
5
Application of next generation sequencing in the diagnosis and management of mast cell leukemia. ( 27104182 )
2016
6
A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data. ( 27104187 )
2016
7
Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. ( 26876592 )
2016
8
Extramedullary Involvement of Mast Cell Leukemia Detected by 18F-FDG PET/CT. ( 26975014 )
2016
9
Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. ( 26055303 )
2015
10
Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. ( 25443885 )
2015
11
De novo leukemic variant of mast cell leukemia with KIT D816V. ( 25729733 )
2015
12
Mast cell leukemia: an extremely rare disease. ( 25028296 )
2014
13
Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. ( 25209843 )
2014
14
Mast cell leukemia with prolonged survival on PKC412/midostaurin. ( 25031773 )
2014
15
FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. ( 24596674 )
2014
16
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. ( 24675021 )
2014
17
Mast cell leukemia associated with undefined morphology and chronic basophilic leukemia. ( 25264491 )
2014
18
Sustained paranoid psychosis in a patient with mast cell leukemia and decreased serotonin level. ( 23793328 )
2013
19
A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation. ( 23483057 )
2013
20
The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis. ( 23504229 )
2013
21
A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17. ( 24034180 )
2013
22
Mast cell leukemia. ( 23243287 )
2013
23
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. ( 22324351 )
2012
24
Aleukemic variant of mast cell leukemia. ( 22482127 )
2012
25
Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor I^ chain and KIT V654A. ( 22173243 )
2012
26
Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm. ( 22661384 )
2012
27
Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. ( 22329485 )
2012
28
Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. ( 21261503 )
2011
29
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. ( 20658589 )
2010
30
Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. ( 20485374 )
2010
31
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). ( 20688965 )
2010
32
Mast cell leukemia with rapidly progressing portal hypertension. ( 19883434 )
2009
33
Mast cell leukemia: a report of ten cases. ( 18172645 )
2008
34
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. ( 17949810 )
2008
35
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. ( 16543062 )
2006
36
Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras. ( 15735740 )
2005
37
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. ( 15972446 )
2005
38
Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. ( 15928938 )
2005
39
Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. ( 15512820 )
2004
40
Mast cell leukemia. ( 12564414 )
2003
41
Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs. ( 12688323 )
2003
42
Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation. ( 12815487 )
2003
43
Malignant hematopoietic cell lines: in vitro models for the study of mast cell leukemia. ( 12801523 )
2003
44
RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function. ( 11956218 )
2002
45
Low back pain and myalgias in acute and relapsed mast cell leukemia: a case report. ( 12048668 )
2002
46
Mast cell leukemia--a rare form of myeloid leukemia. ( 12238304 )
2002
47
Synaptotagmin I expression in mast cells of normal human tissues, systemic mast cell disease, and a human mast cell leukemia cell line. ( 11181737 )
2001
48
Connective tissue-type mast cell leukemia in a dog. ( 10720189 )
2000
49
Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. ( 10072109 )
1999
50
Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. ( 9149916 )
1997

Variations for Mast-Cell Leukemia

ClinVar genetic disease variations for Mast-Cell Leukemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913507 GRCh37 Chromosome 4, 55599321: 55599321

Expression for Mast-Cell Leukemia

Search GEO for disease gene expression data for Mast-Cell Leukemia.

Pathways for Mast-Cell Leukemia

Pathways related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 BTK CCL2 CCL5 KDR KIT KITLG
2
Show member pathways
13.25 BTK CCL2 CCL5 KDR KIT KITLG
3
Show member pathways
13.1 BTK CCL2 CCL5 KDR KIT KITLG
4
Show member pathways
13.06 CCL2 CCL5 KIT KITLG RASGRP4
5
Show member pathways
13 BTK KDR KIT KITLG NTRK3
6
Show member pathways
12.85 BTK CCL2 CCL5 KDR KIT KITLG
7
Show member pathways
12.72 BTK KDR KIT KITLG NTRK3
8
Show member pathways
12.68 CCL2 KDR KIT KITLG NTRK3
9
Show member pathways
12.4 KDR KIT KITLG RASGRP4
10
Show member pathways
12.23 BTK CCL2 CCL5 KDR KIT KITLG
11
Show member pathways
11.89 BTK KIT KITLG
12 11.85 BTK CCL2 CCL5 KIT KITLG
13 11.71 BTK KDR KIT KITLG
14 11.27 CCL2 CCL5
15 11.25 KIT KITLG
16 11.17 KIT KITLG
17 10.94 BTK CCL2 CCL5
18 10.7 KIT KITLG

GO Terms for Mast-Cell Leukemia

Cellular components related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.28 BTK CCL2 CCL5 KDR KIT KITLG
2 mast cell granule GO:0042629 8.96 BTK KIT

Biological processes related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.94 BTK KDR KIT NTRK3
2 positive regulation of cell proliferation GO:0008284 9.91 KDR KIT KITLG NTRK3
3 protein phosphorylation GO:0006468 9.85 BTK CCL2 KDR KIT NTRK3
4 positive regulation of GTPase activity GO:0043547 9.83 CCL2 CCL5 KIT KITLG RASGRP4
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.79 CCL2 CCL5 KDR
6 regulation of cell shape GO:0008360 9.75 CCL2 KDR KIT
7 positive regulation of cell migration GO:0030335 9.71 CCL5 KDR KIT NTRK3
8 cell chemotaxis GO:0060326 9.67 CCL2 CCL5 KIT
9 protein autophosphorylation GO:0046777 9.67 BTK KDR KIT NTRK3
10 positive regulation of cell adhesion GO:0045785 9.65 CCL2 CCL5
11 peptidyl-tyrosine autophosphorylation GO:0038083 9.65 BTK KDR
12 monocyte chemotaxis GO:0002548 9.65 CCL2 CCL5
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 CCL5 KDR KIT
14 ovarian follicle development GO:0001541 9.64 KIT KITLG
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.63 CCL2 CCL5
16 cellular response to fibroblast growth factor stimulus GO:0044344 9.63 CCL2 CCL5
17 response to tumor necrosis factor GO:0034612 9.62 CCL2 CCL5
18 peptidyl-tyrosine phosphorylation GO:0018108 9.62 BTK KDR KIT NTRK3
19 positive regulation of JAK-STAT cascade GO:0046427 9.61 CCL5 KIT
20 positive regulation of Ras protein signal transduction GO:0046579 9.6 KITLG RASGRP4
21 positive regulation of monocyte chemotaxis GO:0090026 9.59 CCL2 CCL5
22 positive regulation of synaptic transmission GO:0050806 9.58 CCL2 SYT1
23 positive regulation of leukocyte migration GO:0002687 9.57 CCL2 KITLG
24 positive regulation of macrophage chemotaxis GO:0010759 9.56 CCL2 CCL5
25 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.55 CCL2 KDR
26 macrophage chemotaxis GO:0048246 9.54 CCL2 CCL5
27 positive regulation of positive chemotaxis GO:0050927 9.52 KDR NTRK3
28 ectopic germ cell programmed cell death GO:0035234 9.51 KIT KITLG
29 MAPK cascade GO:0000165 9.35 CCL2 CCL5 KIT KITLG RASGRP4
30 embryonic hemopoiesis GO:0035162 9.33 KDR KIT KITLG
31 protein kinase B signaling GO:0043491 9.26 CCL2 CCL5
32 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.02 BTK KDR KIT NTRK3 RASGRP4

Molecular functions related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.71 BTK KDR KIT NTRK3
2 cytokine activity GO:0005125 9.54 CCL2 CCL5 KITLG
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.5 KIT KITLG RASGRP4
4 chemokine activity GO:0008009 9.43 CCL2 CCL5
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 KDR KIT NTRK3
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 KDR KIT
7 protein tyrosine kinase activity GO:0004713 9.26 BTK KDR KIT NTRK3
8 protein kinase activity GO:0004672 9.1 BTK CCL2 CCL5 KDR KIT NTRK3

Sources for Mast-Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....